Story perspectives
Incyte Unveils Drug Launch Plans at J.P. Morgan Conference
1/13/2025
30 7
1 of 1
Story summary
- Incyte presents at the J.P. Morgan Healthcare Conference, focusing on commercial growth and clinical advancements.
- CEO Hervé Hoppenot identifies 2025 as crucial, anticipating several significant drug launches by 2030.
- Highlights include the Niktimvo™ launch for chronic graft-versus-host disease and positive tafasitamab data for lymphoma.
- The San Francisco conference has increased security measures due to recent healthcare sector violence.
